ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 86.40% for the 12-month period ending 2023-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-12-31 was 115.00%, a 4.55% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2017-12-31 was 110.00%, a 39.24% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2016-12-31 was 79.00%, a 11.24% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-12-31 was 89.00%, a 18.67% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 86.40%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 115.00%, a 4.55% increase from fiscal 2018.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2018 was 110.00%, a 39.24% increase from fiscal 2017.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2017 was 79.00%, a 11.24% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2023-09-30 | 86.40% 10-K · filed 2025-11-25 | |||
| 2023-06-30 | 86.40% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 86.40% 10-Q · filed 2023-05-02 | |||
| 2019-09-30 | 115.00% 10-K · filed 2021-11-22 | |||
| 2019-06-30 | 115.00% 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | 115.00% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 115.00% 10-Q · filed 2020-02-05 | |||
| 2018-09-30 | 110.00% 10-K · filed 2020-11-23 | |||
| 2018-06-30 | 110.00% 10-Q · filed 2019-08-05 | |||
| 2018-03-31 | 110.00% 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 110.00% 10-Q · filed 2019-02-07 | |||
| 2017-09-30 | 79.00% 10-K · filed 2019-11-25 | |||
| 2017-06-30 | 79.00% 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | 79.00% 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 79.00% 10-Q · filed 2018-02-09 | |||
| 2016-09-30 | 89.00% 10-K · filed 2018-12-11 | |||
| 2016-06-30 | 89.00% 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | 89.00% 10-Q · filed 2017-05-03 | |||
| 2015-12-31 | 89.00% 10-Q · filed 2017-02-06 | |||
| 2015-09-30 | 75.00% 10-K · filed 2017-12-12 | |||
| 2015-06-30 | 75.00% 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | 75.00% 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | 75.00% 10-Q · filed 2016-02-09 | |||
| 2014-09-30 | 69.00% 10-K · filed 2016-12-14 | |||
| 2014-06-30 | 69.00% 10-Q · filed 2015-08-04 | |||
| 2014-03-31 | 69.00% 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | 69.00% 10-Q · filed 2015-02-09 | |||
| 2013-09-30 | 69.00% 10-K · filed 2015-12-14 | |||
| 2013-06-30 | 69.00% 10-Q · filed 2014-08-12 | |||
| 2013-03-31 | 69.00% 10-Q · filed 2014-05-06 | |||
| 2012-12-31 | 69.00% 10-Q · filed 2014-02-04 | |||
| 2011-12-31 | 100.00% 10-Q · filed 2013-02-13 | |||
| 2011-09-30 | 100.00% 10-K · filed 2012-12-28 | |||
| 2011-06-30 | 100.00% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |